373 related articles for article (PubMed ID: 2564628)
1. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies.
Politi PM; Arnold ST; Felsted RL; Sinha BK
Mol Pharmacol; 1990 Jun; 37(6):790-6. PubMed ID: 1972771
[TBL] [Abstract][Full Text] [Related]
3. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Versantvoort CH; Broxterman HJ; Pinedo HM; de Vries EG; Feller N; Kuiper CM; Lankelma J
Cancer Res; 1992 Jan; 52(1):17-23. PubMed ID: 1309222
[TBL] [Abstract][Full Text] [Related]
4. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
5. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
Nakagawa M; Schneider E; Dixon KH; Horton J; Kelley K; Morrow C; Cowan KH
Cancer Res; 1992 Nov; 52(22):6175-81. PubMed ID: 1358431
[TBL] [Abstract][Full Text] [Related]
6. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
7. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
Chen G; Teicher BA; Frei E
Anticancer Res; 1996; 16(6B):3499-505. PubMed ID: 9042212
[TBL] [Abstract][Full Text] [Related]
8. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
9. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A.
Gollapudi S; Gupta S
Anticancer Res; 1992; 12(6B):2127-32. PubMed ID: 1363515
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
11. Relationship of VP-16 to the classical multidrug resistance phenotype.
Sehested M; Friche E; Jensen PB; Demant EJ
Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902
[TBL] [Abstract][Full Text] [Related]
12. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.
Gervasoni JE; Fields SZ; Krishna S; Baker MA; Rosado M; Thuraisamy K; Hindenburg AA; Taub RN
Cancer Res; 1991 Sep; 51(18):4955-63. PubMed ID: 1680024
[TBL] [Abstract][Full Text] [Related]
13. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
15. Differential oncogene expression and susceptibility to apoptosis in the human leukemia HL60 cell lines: implications for etoposide resistance.
Eliot HE; Borner MM; Sinha BK
Anticancer Res; 1995; 15(3):729-33. PubMed ID: 7645949
[TBL] [Abstract][Full Text] [Related]
16. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J
Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein.
Marquardt D; McCrone S; Center MS
Cancer Res; 1990 Mar; 50(5):1426-30. PubMed ID: 1967979
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
20. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
Evans CH; Baker PD
Cancer Res; 1992 Nov; 52(21):5893-9. PubMed ID: 1356622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]